What is the current price of intra-cellular therapies'stock?
Since then, ITCI stock has increased by 171.2% and is now trading at $48.20. View which stocks have been most impacted by COVID-19. When is Intra-Cellular Therapies' next earnings date? Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
Is intra-cellular therapies Inc (ICTI) a good growth stock to buy?
SVP of Finance CFO of Intra-cellular Therapies Inc (30-Year Financial, Insider Trades) Lawrence J. Hineline (insider trades) sold 175,000 shares of ITCI on 12/21/2021 at an average price of $47.59 a share. The past 20 months have been good for growth stocks, to say the least.
Does intra-cellular therapies boast high insider ownership?
13.20% of the stock of Intra-Cellular Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health. 81.68% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
What was the earnings release for intra-cellular therapies Inc (ITCI)?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.83) by $0.15.
See more
When did intra-cellular therapies go public?
March 5, 2015Intra-Cellular Therapies Prices $114 Million Public Offering of Common Stock. NEW YORK , March 5, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.
What does intra-cellular therapies inc do?
Description. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.
Should I buy Itci stock?
The financial health and growth prospects of ITCI, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Is intra-cellular therapies a buy?
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Who owns Intra-Cellular Therapies?
As Founder, Chairman and CEO of Intra-Cellular Therapies, Inc. (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative drugs that address underserved medical needs in complex psychiatric and neurologic diseases.
How many employees does Intra-Cellular Therapies have?
Intra-Cellular Therapies total number of employees in 2020 was 383, a 16.06% increase from 2019. Intra-Cellular Therapies total number of employees in 2019 was 330, a 352.05% increase from 2018. Intra-Cellular Therapies total number of employees in 2018 was 73, a 48.98% increase from 2017.
Who manufactures Caplyta?
FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults | Intra-Cellular Therapies Inc.
Where is intra-cellular?
Intra-Cellular Therapies Inc, 3960 Broadway, New York, NY 10032.
What is interstellar therapy?
Makryannis, Interstellar Therapeutics aims to tackle the problem of addiction by implementing a kind of medication different from opioid-based treatments.
Should I buy or sell Intra-Cellular Therapies stock right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1...
What is Intra-Cellular Therapies' stock price forecast for 2022?
7 brokers have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $40.00 to $70.00. On average, they...
How has Intra-Cellular Therapies' stock performed in 2022?
Intra-Cellular Therapies' stock was trading at $52.34 at the beginning of 2022. Since then, ITCI stock has increased by 1.3% and is now trading at...
Are investors shorting Intra-Cellular Therapies?
Intra-Cellular Therapies saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 3,120,000 shar...
When is Intra-Cellular Therapies' next earnings date?
Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast f...
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($...
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the following people: Dr. Sharon Mates Ph.D. , Co-Founder, Chairman, CEO & Pres (Age 69, Pay...
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include Horizon Therapeutics Public (HZNP) , Catalent (CTLT) , Genmab A/S (GMAB) ,...
What other stocks do shareholders of Intra-Cellular Therapies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Th...
About Intra-Cellular Therapies
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.
Content From Our Affiliates
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 6 buy ratings for the stock.
Profile
Intra-Cellular Therapies, Inc. is a biopharmaceutical company.
What is intracellular therapy?
Intra-Cellular Therapies, Inc. is a biopharmaceutical company.
What is CAPLYTA used for?
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States . The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson’s disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
